Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 7/20 | 0.38 |
| ▸ | CASP7 | P55210 | 7/20 | 0.38 |
| ▸ | CASP9 | P55211 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 2/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.36 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3441884 | 0.89 | CASP3 (0.38) | CASP3CASP7CASP9HTR7TMEM97 | |
| SCHEMBL3441856 | 0.89 | HTR7 (0.41) | CASP3CASP7HTR7TMEM97SIGMAR1 | |
| SCHEMBL15267624 | 0.88 | CASP3 (0.49) | CASP3CASP7CASP9HTR7TMEM97 | |
| SCHEMBL13587278 | 0.86 | CASP3 (0.41) | CASP3CASP7CASP9HTR7BDKRB1 | |
| SCHEMBL13587101 | 0.85 | CASP3 (0.41) | CASP3CASP7CASP9HTR7TMEM97 | |
| SCHEMBL640467 | 0.84 | CASP3 (0.40) | CASP3CASP7CASP9HTR7TMEM97 | |
| SCHEMBL700919 | 0.84 | BDKRB1 (0.41) | CASP3CASP7NPC1RAB9ABDKRB1 | |
| SCHEMBL700918 | 0.84 | BDKRB1 (0.41) | CASP3CASP7NPC1RAB9ABDKRB1 | |
| SCHEMBL3764045 | 0.84 | BDKRB1 (0.41) | CASP3CASP7NPC1RAB9ABDKRB1 | |
| SCHEMBL3764050 | 0.84 | BDKRB1 (0.41) | CASP3CASP7NPC1RAB9ABDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124624-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-02-28 | — | — | US | disclosed |
| EP-2262792-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2010-12-22 | — | — | EP | disclosed |
| US-20090264407-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-22 | — | — | US | disclosed |
| WO-2009124733-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2009-10-15 | — | — | WO | disclosed |
| US-20090253669-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264407-A1 | Substituted Sulfonamide Compounds | CNR1, SUCNR1, OPRL1 | CASP3 4032/4885CASP7 4389/4885CASP9 3663/4885 |
| US-20090253669-A1 | Substituted Sulfonamide Compounds | SULT2A1, STS, SULT1A1 | CASP3 3151/4885CASP7 2958/4885CASP9 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.